Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, Kim HR. Kim CG, et al. Among authors: kim h, kim g, kim hj, kim d, kim sh, kim schulze s, kim c, kim s, kim hr, kim kh, kim jh. Clin Cancer Res. 2024 May 15;30(10):2097-2110. doi: 10.1158/1078-0432.CCR-23-3249. Clin Cancer Res. 2024. PMID: 38457288 Clinical Trial.
Prognosis of pN3 stage gastric cancer.
Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Ahn JR, et al. Among authors: kim c, kim hr. Cancer Res Treat. 2009 Jun;41(2):73-9. doi: 10.4143/crt.2009.41.2.73. Epub 2009 Jun 30. Cancer Res Treat. 2009. PMID: 19707504 Free PMC article.
Clinical value of ezrin expression in primary osteosarcoma.
Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Kim C, et al. Among authors: kim hr. Cancer Res Treat. 2009 Sep;41(3):138-44. doi: 10.4143/crt.2009.41.3.138. Epub 2009 Sep 28. Cancer Res Treat. 2009. PMID: 19809563 Free PMC article.
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Kim HS, Kim HR, Kim GM, Kim HS, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC. Kim HS, et al. Among authors: kim sh, kim gm, kim hr, kim sm, kim jh. Cancer Chemother Pharmacol. 2012 Oct;70(4):539-46. doi: 10.1007/s00280-012-1933-8. Epub 2012 Aug 7. Cancer Chemother Pharmacol. 2012. PMID: 22868340
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Kim HS, et al. Among authors: kim sb, kim b, kim sh, kim tm, kim hr, kim jh. Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25. Clin Cancer Res. 2015. PMID: 25424851 Clinical Trial.
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.
Huang KK, Jang KW, Kim S, Kim HS, Kim SM, Kwon HJ, Kim HR, Yun HJ, Ahn MJ, Park KU, Ramnarayanan K, McPherson JR, Zhang S, Rhee JK, Vettore AL, Das K, Ishimoto T, Kim JH, Koh YW, Kim SH, Choi EC, Teh BT, Rozen SG, Kim TM, Tan P, Cho BC. Huang KK, et al. Among authors: kim sh, kim s, kim tm, kim sm, kim hr, kim hs, kim jh. Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552. Sci Rep. 2016. PMID: 26790612 Free PMC article.
3,227 results